Skip to main content

Table 1 Patients’ characteristics

From: Impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases

 

Groupe 1

Concomitant

N = 99 (171 metastases)

%

Group 2

Non concomitant

N = 95 (131 metastases)

%

Difference p-value

Gender

    

0.124

 Female

49

49

36

38

 

 Male

50

51

59

62

 

KPS median (range)

90

(60–100)

90

(60–100)

0.230

Age median (range)

61

(38–85)

60

(24–84)

0.530

Primary

 Lung

60/99

60

70/95

75

0.004

  EGFR+

18/60

30

1/70

1.5

 

  ALK+

7/60

12

3/70

4

 

  PDL1 > 1%

26/60

43

1/70

1.5

 

 Breast

19/99

19

9/95

9

0.177

  HER2+++

13/19

68

1/9

11

 

 Melanoma

13/99

13

4/95

4

0.049

 GU

2/99

2

4/95

4

0.987

 GI

5/99

5

8/95

8

0.461

Number of BMs (range)

2

(1–5)

2

(1–7)

0.998

Tumor size (cm)

 < 2 cm

129/171

76

88/131

67

0.109

 2-3 cm

28/171

16

32/131

25

0.072

 > 3 cm

14/171

8

11/131

8

0.831

Prior WBRT

 Yes

25

25

24

26

0.995

 No

74

74

71

74

 

DS GPA (range)

2,5

(0.5–3.5)

2,5

(0.5–3.5)

0.999

RPA

 I

18/99

18

45/95

47

< 0.001

 II

78/99

79

47/95

50

< 0.001

 III

3/99

3

3/95

3

0.673

ECM

 Yes

56

56

32

34

0.002

 No

43

43

63

66

 

Treatments

 CT

33/99

33

64/95

67

< 0.001

  Before

14/33

 

48/64

  

  After

23/33

 

19/64

  

 IT

30/99

30

6/95

6

< 0.001

  Before

15/30

 

4/6

  

  After

16/30

 

2/6

  

 TT

36/99

36

17/95

18

0.031

  Before

22/36

 

9/17

  

  After

27/33

 

8/17

  

 HT

4/99

4

1/94

1

0.403

Dosimetric parameters

 HG

87/171

51

65/131

49

0.783

 INH

84/171

49

66/131

51

 
  1. Abbreviations: KPS Karnofsky Performance Status, EGFR Epidermal Growth Factor Receptor, ALK Anaplastic lymphoma kinase, PLD1 Programmed death-ligand 1, HER2 Human Epidermal Growth Factor Receptor-2, GU Genito-urinary, GI Gastro-Intestinal, BM Brain metastases, WBRT Whole brain radiotherapy, DS-GPA Diagnostic-Specific Graded Prognostic Assessment, RPA Recursive partitioning analysis, ECM Extracranial metastases, CT Chemotherapy, IT Immunotherapy, TT Targeted therapy, HT Hormonotherapy, HG Homogeneous, INH Inhomogeneous